Cell Line Development Services for Astrocytoma
Astrocytes provide structural and metabolic support to the brain and neurons, modulate ion concentrations in the extracellular gaps, regulate synaptic transmission, and uptake and release neurotransmitters. They are an integral part of the blood-brain barrier. Astrocytomas are primary brain tumors that originate from astrocytes. Although a small number of low-grade astrocytomas are benign, the majority of these tumors are malignant and often lead to a poor prognosis.
We offer services for astrocytoma cell line development
Cell lines are often used as astroglioma models because they are easier, faster to perform, and less costly. Alfa Cytology' astrocytoma cell line development service can help you find valuable biomarker molecules for brain astrocytoma and, hopefully, identify candidate targets for gene therapy of malignant brain astrocytoma, providing a new strategy for gene therapy of brain malignant astrocytoma.
Development flow
Our cell lines were developed through the steps of sampling, constructing (primary and passaged culture by tissue block culture method and single cell culture method), and cell characteristics observation.
- Cell morphology. Light microscopy morphology and transmission electron microscopy are present.
- Cell growth characteristics. Cell growth curve, cell division index, plate colony effect.
- Chromosome analysis. After hypotonicity, fixation, filming and drying, staining, and light microscopic examination, it was observed that the chromosome morphology was significantly abnormal and had the characteristics of malignant tumor cells.
- Immunocytochemical staining for astrocyte marker protein (GFAP). It was positive, proving that it was indeed a malignant tumor of astrocytic origin.
Successfully developed astrocytoma cell lines
The astrocytoma cell line we provide is a mature adnexal fibroblast cell line obtained from human brain astrocytoma tissue after shearing, digestion, culturing, passaging, and identification. It can be used for in vitro studies of astrocytoma cells.
- U-118 MG
- U-87 MG
- U251 MG/TMZ (drug resistant)
- U251 MG
- BT325
- SHG44
- Becker
- SW1783
- SW1088
- SMA-560 (mouse)
Advantages
- Can be used for subcutaneous tumor formation in mice.
- Passes bacterial, fungal, mycoplasma, and endotoxin assays.
- Pass cell recovery viability assay, recovery survival rate >90%.
- Pass STR assay.
We additionally provide human astrocytoma stem cell isolation and identification services to form a complete cell line development system. We use the direct culture method to isolate and culture astrocytoma stem cells. We observe their proliferation and differentiation and perform immunocytochemical identification of nestin and CD133, and immunocytochemical identification of neuron-specific enolase, glial fibrillary acidic protein, and O4 after induction of differentiation.
- Isolation and culture of tumor stem cells. Observation of tumor stem cell growth in primary and passaged cultures.
- Clone formation assay. Single-cell inoculation for 5-7 d to form clone spheres.
- Identification of tumor stem cells. Immunocytochemical staining showed cells were immunopositive for nestin, CD133.
- Induction of differentiation in vitro. Adjacent cell protrusions were interconnected to form a network between cell balls, and differentiated cells had multiple morphology and obvious heterogeneity.
Case Study - SF-268 Xenograft Model
Model Introduction
The SF-268 xenograft model is a well-established preclinical platform for studying glioblastoma and other central nervous system tumors. SF-268 is a human glioblastoma/astrocytoma cell line originally derived from a central nervous system tumor, identified as highly anaplastic, highly proliferative, and aggressive. This model is particularly valuable for evaluating the efficacy of novel anticancer therapies, investigating tumor growth mechanisms, and studying resistance to chemotherapy and radiation. SF-268 is also part of the National Cancer Institute's NCI-60 panel of cell lines used for standard screening of potential anticancer compounds.
Model Information
- Model: SF-268 Xenograft Model
- Animals: NOD-SCID Mice
- Age: 10-12 Weeks
Model Construction
The model is established by subcutaneously implanting human SF-268 glioblastoma cells into the hind leg flank of immunocompromised mice. Cell inoculum is 1×10⁶ cells/mouse in 50% Matrigel solution, with a total injection volume of 100 µL. Tumor growth is monitored by palpation tri-weekly until tumors reach 100–150 mm³, at which point treatment is initiated.
Fig. 1 Workflow of SF-268 xenograft model establishment. (Source: Alfa Cytology)
Model Data
- Tumorigenicity: IOMM-Lee cells demonstrate consistent and reproducible tumor formation in athymic mice, with 100% engraftment rate and localized growth at the skull base.
- Growth Kinetics: Tumor growth is progressive, with consistent survival times ranging from 17–21 days post-implantation. Histopathological analysis reveals skull invasion, brain invasion along perivascular tracts, and the emergence of hypoxia and necrosis by day 9 and day 12, respectively.
- Therapeutic Efficacy: Drug A (25 mg/kg) significantly suppressed SF-268 xenograft tumor growth, reducing tumor volume by approximately 74% at day 35 compared to the control group.
Fig. 2 Representative tumor growth curves of SF-268 subcutaneous xenograft model. Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
Alfa Cytology offers astrocytoma cell line development to provide a better cellular model for the investigation of the mechanism of carcinogenesis, observation of tumor biology, drug screening, monoclonal antibodies against astrocytoma-associated antigens, and preparation of lead drugs. Please feel free to contact our staff for details so that we can customize an astrocytoma cell line to meet your research needs as soon as possible.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
